{"Symbol": "ADXN", "AssetType": "Common Stock", "Name": "Addex Therapeutics Ltd", "Description": "Addex Therapeutics Ltd, a developing-stage biopharmaceutical company, discovers, develops and markets small molecule pharmaceuticals for central nervous system (CNS) disorders in Switzerland. The company is headquartered in Geneva, Switzerland.", "CIK": "1574232", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "CHEMIN DES MINES, 9, GENEVA, SWITZERLAND, 1202", "OfficialSite": "https://www.addextherapeutics.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "9289400", "EBITDA": "-2456840", "PERatio": "None", "PEGRatio": "None", "BookValue": "0.0664", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-9.36", "RevenuePerShareTTM": "0.24", "ProfitMargin": "0", "OperatingMarginTTM": "-14.04", "ReturnOnAssetsTTM": "-0.159", "ReturnOnEquityTTM": "-0.728", "RevenueTTM": "158540", "GrossProfitTTM": "-525653", "DilutedEPSTTM": "-9.36", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.15", "AnalystTargetPrice": "30", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "58.59", "PriceToBookRatio": "1.202", "EVToRevenue": "165.71", "EVToEBITDA": "-0.757", "Beta": "1.942", "52WeekHigh": "12.05", "52WeekLow": "6.51", "50DayMovingAverage": "7.96", "200DayMovingAverage": "8.45", "SharesOutstanding": "1232000", "SharesFloat": "93856000", "PercentInsiders": "0.000", "PercentInstitutions": "0.063", "DividendDate": "None", "ExDividendDate": "None"}